Clinical trials: insulin glargine
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
This study will compare hemoglobin a1c (HbA1c) and cardiovascular (CV) outcomes among patients with type 2 diabetes newly initiating a GLP1-receptor agonist or basal insulin.
- Trial name
- NCT04034524
- Testing
- GLP-1 receptor agonist, Insulin
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in…
- Trial name
- NCT02518945
- Testing
- Dapagliflozin, Insulin, Liraglutide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the…
- Trial name
- NCT03107208
- Testing
- Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetic Foot Ulcer
Intensive Glycemic Control For Diabetic Foot Ulcer Healing
With the available molecular and cellular evidence of impaired wound healing due to hyperglycemia, investigators postulate hypothesis asking whether intensive glycemic control could improve diabetic foot ulcer healing rates.
- Trial name
- INGLOBE (NCT04323462)
- Testing
- Insulin Glargine, Diabetic DM
- Where
- 2 sites in India
- Volunteers
- 326 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Type 2 Diabetes Mellitus
Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration
Evaluating patients with type 2 diabetes either starting once daily basal insulin or requiring increased basal titrations in order to compare the LTHome web based tool with the usual standard of practice for insulin glargine…
- Trial name
- INNOVATE (NCT02540486)
- Testing
- Long-acting insulin glargine titration web tool (LTHome), Diabetes Education
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
DM2
Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department
Prospective, open labels, randomized study. A total of 60 admitted patient between 18 and 85 years old with known with history of DM for more than 3 months and an average of two consecutive blood glucose levels above 180 mg/dl…
- Trial name
- NCT03051243
- Testing
- Linagliptin and Basal Insulin, Basal Insulin and Bolus Insulin
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral…
- Trial name
- NCT00437112
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
The rationale of the study is to determine: the first dose and the titration of basal insulin the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
- Trial name
- NCT00349986
- Testing
- Insuline glargine
- Where
- Hungary
- Volunteers
- 4 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in…
- Trial name
- NCT00106366
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 389 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
The study aims to evaluate arterial stiffness and endothelial function indexes and their relationship with clinic and laboratory varible in a group of diabetic patients in treatment with dulaglutide
- Trial name
- NCT03824002
- Testing
- Dulaglutide, Aspart insulin, Glargine
- Where
- Italy
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Type2 Diabetes
The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine
Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. This study aims to investigate the current status of blood glucose control in patients with T2D treated with glargine.
- Trial name
- NCT03566472
- Testing
- Continuous Glucose Monitoring System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Diabetes Mellitus, Type 2
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c =…
- Trial name
- NCT00423215
- Testing
- Insulin glargine (LANTUS)
- Where
- Israel
- Volunteers
- 1,007 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)
Primary objective: To find out an optimal regimen of OHA (oral hypoglycaemic agents) in combination with insulin glargine (metformin, glimepiride or metformin+glimepiride) by measuring HbA1c level Secondary objective: To compare…
- Trial name
- NCT00708578
- Testing
- Glimepiride, Metformin, Insulin Glargine
- Where
- South Korea
- Volunteers
- 99 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Cost Effectiveness of Glargine Insulin Versus NPH Insulin
Glycemic control is fundamental in the management of diabetes mellitus .If lifestyle intervention and full tolerated doses of one or two oral glucose lowering drugs (OGLDs) fail to achieve or sustain glycemic goals, insulin…
- Trial name
- NCT01832935
- Testing
- insulin glargine, Insulin NPH
- Where
- Iran
- Volunteers
- 200 people
- Sponsor
- Tehran University of Medical Sciences
Diabetes Mellitus, Type 2
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
The purpose of this phase IV clinical trial is to investigate the effect of Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs.
- Trial name
- NCT01206712
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- ikfe-CRO GmbH
Diabetes, Type 2
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes.
- Trial name
- NCT06340854
- Testing
- Insulin icodec, Insulin glargine
- Where
- 83 sites in United States, Bulgaria and 7 more
- Volunteers
- 412 people
- Sponsor
- Novo Nordisk A/S